GC Pharma (006280) - Financial and Strategic SWOT Analysis Review

July 2021 | 55 pages | ID: G3A42E43DD4EN
GlobalData

Abstracts

GC Pharma (006280) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

GC Pharma (GC Pharma) a subsidiary of Green Cross Holdings Corp, provides plasma protein therapeutics and vaccines. The company develops, manufactures and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and antithrombin; vaccines for infectious diseases; prescription drugs for treating cardiovascular, respiratory, central nervous system (CNS), gastrointestinal and immunology diseases, musculoskeletal disorders, genetic disorders, metabolic disorders and haematological disorders; and Over-the-counter (OTC) drugs including anti-inflammatory drugs, anti-allergic products and others. The company focuses its research and development activities at developing drugs for treatment of cancer, tuberculosis, and hunter syndrome, among others. GC Pharma is headquartered Yongin, Gyeonggi-do, South Korea.

GC Pharma Key Recent Developments

Jun 28,2021: GC Green Cross Well-Being completes the production facility for nutritional injections in the Chungbuk Innovation City
Jun 08,2021: mCureX and Samyang sign MoU for mRNA vaccine development
May 24,2021: GC Green Cross Healthcare acquires ISMS-P certification for the first time in the Industry
May 03,2021: GC Pharma : Hector project acquired 'EMR National Standard Certification' by the Ministry of Health and Welfare
Apr 28,2021: GC Pharma Reports Q1 2021 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

GC Pharma - Key Facts
GC Pharma - Key Employees
GC Pharma - Key Employee Biographies
GC Pharma - Major Products and Services
GC Pharma - History
GC Pharma - Company Statement
GC Pharma - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
GC Pharma - Business Description
R&D Overview
GC Pharma - Corporate Strategy
GC Pharma - SWOT Analysis
SWOT Analysis - Overview
GC Pharma - Strengths
GC Pharma - Weaknesses
GC Pharma - Opportunities
GC Pharma - Threats
GC Pharma - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GC Pharma, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
GC Pharma, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 28, 2021: GC Green Cross Well-Being completes the production facility for nutritional injections in the Chungbuk Innovation City
Jun 08, 2021: mCureX and Samyang sign MoU for mRNA vaccine development
May 24, 2021: GC Green Cross Healthcare acquires ISMS-P certification for the first time in the Industry
May 03, 2021: GC Pharma : Hector project acquired 'EMR National Standard Certification' by the Ministry of Health and Welfare
Apr 28, 2021: GC Pharma Reports Q1 2021 Results
Apr 21, 2021: GC Green Cross launches mild contraceptive pill with reduced side effects
Apr 15, 2021: GC Green Cross Well-Being applied for an international patent for placental-derived antiviral composition
Apr 13, 2021: GCL expands its clinical trial sample analysis laboratory
Apr 07, 2021: GC Well-Being, applied for an international patent for a composition for preventing and treating liver disease
Mar 22, 2021: GC Green Cross Lab Cell acquires domestic patent for NK cell manufacturing method

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

GC Pharma, Key Facts
GC Pharma, Key Employees
GC Pharma, Key Employee Biographies
GC Pharma, Major Products and Services
GC Pharma, History
GC Pharma, Other Locations
GC Pharma, Subsidiaries
GC Pharma, Key Competitors
GC Pharma, Ratios based on current share price
GC Pharma, Annual Ratios
GC Pharma, Annual Ratios (Cont...1)
GC Pharma, Annual Ratios (Cont...2)
GC Pharma, Interim Ratios
GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GC Pharma, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
GC Pharma, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

GC Pharma, Performance Chart (2016 - 2020)
GC Pharma, Ratio Charts
GC Pharma, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
GC Pharma, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021